Degradation of the Anorexic Hormone Peptide YY

Early Phase 1

Completed

• Conditions: Healthy
• Interventions: Biological: PYY1-36 infusion; Biological: PYY1-36 + sitagliptin; Biological: PYY3-36 infusion; Biological: placebo

• Registration Number: NCT02493959
• Lead Sponsor: Hvidovre University Hospital

Brief Summary

Peptide YY (PYY) is a gastrointestinal hormone released from the enteroendocrine cell upon food intake. The N-terminal truncated form, PYY3-36, exerts anorexic effects. In this study we want to investigate the kinetics of PYY1-36 and PYY3-36 and to examine whether a C-terminally degraded metabolite, PYY3-34, is formed after infusion of PYY.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05
• Status Verified: 2015-07
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Study First Submitted: 2015-07-02
• Study First Submitted QC: 2015-07-09
• Last Update Submitted: 2015-07-09
• Study First Posted: 2015-07-10
• Last Update Posted: 2015-07-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 8

Inclusion Criteria

• Healthy
• Normal BMI (18.5-25kg/m2)

Exclusion Criteria

• Diabetes Mellitus
• Gastric bypass
• Non-caucasian
• Height changes >3 kg within last two months
• Hemoglobin < 7.6 mmol/l
• Chronic disease
• Smoking
• Regularly use of medicine
• Drug abuse

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
PYY infusion	placebo	IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
PYY infusion	PYY3-36 infusion	IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
PYY infusion	PYY1-36 infusion	IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
PYY infusion	PYY1-36 + sitagliptin	IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years

Primary Outcome Measures

Name	Time	Method
Half-lives of PYY1-36 and PYY3-36	0-240 min
PYY3-34 concentration	0-240 min

Trial Locations

Locations (1)

Department of Endocrinology, Hvidovre Hospital; 🇩🇰 Hvidovre, Denmark